

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF Art Unit: 1614

Kitaoka, Kenichi et al. Examiner:

INTERNATIONAL APPLICATION NO: PCT/EP2004/006865

FILED: June 24, 2004

U.S. APPLICATION NO: 10/560940

35 USC §371 DATE: December 15, 2005

FOR: Tablet Comprising Fluvastatin and Carmellose Calcium

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

supplemental to the Information Disclosure Statement filed March 6, 2007.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c) or 37 C.F.R. §1.97(d).


A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Jennifer C. Chapman
Attorney for Applicant
Reg. No. 47,487

Novartis
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-1202

Date: *July 7, 2008*